[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Roswell Park Cancer Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":535},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,63,0,25,[9,42,62,88,108,129,151,170,192,212,234,254,274,294,329,349,368,387,403,424,442,462,478,496,516],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100635525","home-based-respiratory-muscle-training-and-aerobic-exercise-programs-to-improve-lung-health-in-current-and-former-cigarette-smokers-100635525",false,"NCT07553819","Home-Based Respiratory Muscle Training and Aerobic Exercise Programs to Improve Lung Health in Current and Former Cigarette Smokers","Effects of Respiratory Muscle Training and Aerobic Exercise on Lung Health in Smokers: A Pilot Parallel-Group Study for Lung Cancer Prevention","Inclusion Criteria:\n\n* Age ≥ 50 years old\n* Current smoker with a ≥ 20-pack-years history\n* Former smoker within the past 15 years, with a history of ≥ 20 pack-years (CT scan cohort only)\n* Participant must be able to speak, read and comprehend English language\n* Cognitively capable of following direction and performing the intervention\n* Understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Any previous lung cancer diagnoses and or undergoing treatment for any cancer\n* Recent pneumonia, bronchitis, or other inflammatory conditions in the lungs, including but limited to chronic obstructive pulmonary disease (COPD) and\u002For asthma exacerbation within the previous 6 months\n* Have uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, heart failure or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study intervention",true,"ALL","50 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical trial studies whether home-based respiratory muscle training (RMT) and aerobic exercise (AE) programs can be used to improve lung health in current and former cigarette smokers. Lung cancer, the leading cause of cancer death, is overwhelmingly caused by exposure to cigarette smoke. Research suggests that daily activity reduces lung cancer risk in current and former smokers. However, current and former smokers are generally not active and new approaches to improve lung health are needed. During the home-based RMT program, participants use a handheld device to complete breathing exercise sessions consisting of breathing in and out against adjustable resistance. During the home-based AE program, participants complete aerobic exercises using a stationary bike working at a moderate workload against adjustable resistance. The home-based RMT and AE programs may be effective ways to strengthen the breathing muscles, which may improve lung health in current and former cigarette smokers.",[28],"Lung Carcinoma","NOT_YET_RECRUITING","2026-08-20",{"date":32,"type":33},"2026-08-21","ACTUAL",{"date":35,"type":22},"2026-09-15",{"date":37,"type":22},"2029-05-01",{"name":39,"class":40},"Roswell Park Cancer Institute","OTHER",1,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":56,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":41},"100507941","low-intensity-mechanical-stimulation-for-hematologic-malignancy-patients-100507941","NCT05893940","Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients","Inclusion Criteria:\n\n* COHORT I: Meet eligibility criteria for first autologous or allogeneic HCT (patients with preexisting osteoporosis are eligible)\n* COHORT I: Scheduled to undergo an autologous or allogeneic HCT\n* COHORT 1: \\>= 18 years of age\n* COHORT 1: Patient must understand the investigational nature of this study and sign an institutional review board approved written informed consent form prior to receiving any study related procedure\n\n  \\- COHORT II: ≥ 18 years of age\n* COHORT II: Diagnosis of non-Hodgkin lymphoma (specifically diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia; patients with preexisting osteoporosis are eligible)\n* COHORT II: Patient must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\nCOHORT 1:\n\n* Any prior allogeneic HCT\n* Any prior autologous HCT for those patients who have a planned auto HCT\n* Pre-transplant weight \\>= 275 lbs. (max weight for the board)\n* Body mass index (BMI) \\\u003C 18 kg\u002Fm\\^2\n* Recipient of cord blood transplant\n* Multiple myeloma or amyloidosis diagnosis\n* History of a central nervous system (CNS) hemorrhage \\\u003C 60 days\n* History of any aneurysm (cerebral, aortic, etc.)\n* A recent pulmonary embolism or deep vein thrombosis\n* A cardiac pacemaker\n* Prior history of non-traumatic (spontaneous) fracture\n* Total joint replacement (any joint)\n* History of kidney stones or gall stones within the last 2 years unless a cholecystectomy was performed\n* Any prosthetic lower extremity or limb\n* Pregnant or nursing female patients\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the Investigator's opinion deems the patient an unsuitable candidate to receive study intervention\n\nCOHORTII:\n\n* Planned CAR T-cell therapy within the next 2 months\n* Prior CAR T-cell therapy\n* Active treatment within the last 60 days\n* Pre-transplant weight ≥ 275 lbs. (max weight for the board)\n* BMI \\\u003C 18 kg\u002Fm\\^2\n* History of a CNS hemorrhage \\\u003C 60 days\n* History of any aneurysm (cerebral, aortic, etc.)\n* A recent pulmonary embolism or deep vein thrombosis\n* A cardiac pacemaker\n* Recent history (\\\u003C 60 days) of non-traumatic (spontaneous) fracture\n* Recent surgery (\\\u003C 60 days)\n* Pregnant or nursing female patients\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the investigator's opinion deems the patient an unsuitable candidate to receive study intervention","18 Years",{"count":50,"type":22},75,[25],"This clinical trial tests the effect of low-intensity mechanical stimulation (LIMS) vibration therapy in patients with hematologic malignancies. Patients with hematologic malignancies often undergo a blood and\u002For bone marrow transplant (hematopoietic cell transplantation \\[HCT\\]) or cellular therapy. The LIMS board delivers vibrations through the bones that may stimulate bone growth and may also increase muscle activity and strength and may also increase T-cell activation in patients planning to undergo cellular therapy. LIMS vibration therapy may stop or reverse BMD loss and\u002For improve the development of T-cells in the body in patients with hematologic malignancies who are undergoing or may plan to undergo HCT or cellular therapies.",[54],"Hematopoietic and Lymphoid System Neoplasm","RECRUITING",{"date":32,"type":33},{"date":58,"type":33},"2023-08-14",{"date":60,"type":22},"2026-12-01",{"name":39,"class":40},{"id":63,"slug":64,"hasResults":12,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":12,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":23,"phases":71,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":82,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":41},"100359833","pulmonary-suffusion-in-controlling-minimal-residual-disease-in-patients-with-sarcoma-or-colorectal-metastases-100359833","NCT03965234","Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases","Phase I\u002F II Study of Pulmonary Suffusion to Control Minimal Residual Disease in Resectable or Ablatable Sarcoma or Colorectal Pulmonary Metastases","Inclusion Criteria:\n\n* Tumors metastatic to the lungs that are the focus of this protocol specifically:\n\n  * Colorectal carcinoma\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of =\\\u003C 2\n* Hemoglobin \\> 8.0 g\u002FL\n* Neutrophils \\> 1,500 uL\n* Platelets \\>= 100,000 uL\n* Creatinine clearance \\>= 30 mL\u002Fmin\n* Clinically diagnosed lung metastases(while preregistration histologic or cytologic confirmation is desirable, this may not be required in clinical scenarios where a biopsy may not change the need to resect suspicious lung nodules or the biopsy itself poses a risk for tumor seeding. In such cases, the diagnosis will be supported by rapid pathologic evaluations intraoperatively before proceeding with Suffusion) Given the emergence of other acceptable options to destroy lung metastases such as stereotactic body radiation therapy (SBRT) or microwave ablation, a hybrid approach to eliminate all sites of disease will be permitted; however, supplemental approaches should be delayed, if possible, until after the 30 day post-suffusion endpoint\n* Pulmonary function judged by the surgeon to be sufficient to tolerate the planned pulmonary metastasectomy. Testing is not required but generally is performed clinically and will be left to the discretion of the treating surgeon. The following are not required but serve as guidelines since they were used to determine eligibility for the Phase I protocol: EV1 \\>= 50% predicted\n* Diffusion capacity of the lung for carbon monoxide (DLCO) \\>= 50% predicted\n* Vital capacity (VC) \\>= 50% predicted\n* Ambulatory and resting oxygen (O2) saturation \\> 88%\n* Six minute walk \\>= 50 % of the expected distance\n* Surgeon affirmation that suffusion and resection or ablation of all nodules is technically feasible\n* Control of the primary tumor as determined by clinical assessment per standard of care; may include stable tumor status of primary tumor and other metastases, in the clinical judgement of the PI\u002Fconsulting physician.\n* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier\n* Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events\n* Allergy, intolerance, or other serious reaction to chemotherapy drugs that may be used in the procedure\n* Pregnant or nursing female participants\n* Unwilling or unable to follow protocol requirements\n* Pulmonary metastases unable to be completely resected or ablated based on pre-registration review of imaging by a thoracic surgeon or proceduralist.\n* Any additional condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug or the suffusion technique, may include uncontrolled intercurrent illness and other conditions that, in the judgement of the PI\u002FPhysician, would limit compliance with the study requirements and have safety concerns\n* Received an investigational agent within 30 days prior to enrollment\n* Severe peripheral neuropathy",{"count":70,"type":22},99,[72,73],"PHASE1","PHASE2","This phase I\u002FII trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with sarcoma or colorectal carcinoma that has spread to the lungs. Pulmonary suffusion is a minimally invasive delivery of chemotherapeutic agents like cisplatin to lung tissues. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pulmonary suffusion may also be useful in avoiding later use of drugs by vein that demonstrate no effect on tumors when delivered locally.\n\nThe Phase 1 portion of the study has been completed.",[76,77,78,79,80,81],"Metastatic Bone Sarcoma","Metastatic Malignant Neoplasm in the Lung","Metastatic Soft Tissue Sarcoma","Metastatic Unresectable Sarcoma","Resectable Sarcoma","Colorectal Cancer",{"date":32,"type":33},{"date":84,"type":33},"2020-07-16",{"date":86,"type":22},"2030-05-25",{"name":39,"class":40},{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":12,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":41},"100647767","comparing-two-weight-loss-programs-for-the-prevention-of-kidney-cancer-progression-among-patients-with-small-renal-masses-on-active-surveillance-100647767","NCT07714018","Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance","Development and Analysis of Weight Loss Programs for Renal Cell Carcinoma Patients on Active Surveillance","Inclusion Criteria:\n\n* English speaking\n* SRM patient with biopsy-confirmed RCC who are initiating or already on AS\n* Age 18 years or older\n* Body mass index (BMI) ≥ 25 kg\u002Fm\\^2\n* No medical problems that might contraindicate participation in a behavioral weight reduction program containing an exercise component\n* No weight loss medication in the past 3 months\n* Not pregnant or lactating\n* No more than 5% body weight loss in the past 3 months\n* No bariatric surgery in the last 10 years\n\nExclusion Criteria:\n\n* Non-English speaking\n* Less than 18 years old\n* BMI \\\u003C 25 kg\u002Fm\\^2\n* Medical problems that might contraindicate participation in a behavioral weight reduction program containing an exercise component\n* On weight loss medication in the past 3 months\n* Pregnant or lactating\n* More than 5% body weight loss in the past 3 months\n* Bariatric surgery in the last 10 years\n* Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drug\n* Unwilling or unable to follow protocol requirements\n* Received an investigational agent within 30 days prior to enrollment",{"count":96,"type":22},20,[25],"This clinical trial compares two different weight-loss programs, daily continuous calorie energy reduction (CER) versus (vs.) 5:2 intermittent fasting (IF), in preventing progression of kidney (renal) cancer among patients with one or more small renal masses (SRM) undergoing active surveillance (AS). Kidney cancer patients tend to have changes in metabolism that may increase body weight, but weight-loss strategies that work for best for these patients are unknown. The CER program requires a set daily limit for calories. The IF program requires fasting for 2 days a week and normal eating for the remaining 5 days. Both will include self-monitoring with interventionist feedback. This trial may help researchers determine whether the IF program works better than the CER program in improving weight loss, physical health, and\u002For reducing the risk of kidney cancer progression among patients with small renal masses undergoing AS",[100],"Renal Cell Carcinoma (RCC)","2026-08-18",{"date":30,"type":33},{"date":104,"type":22},"2026-09-01",{"date":106,"type":22},"2028-09-01",{"name":39,"class":40},{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":41},"100609416","phase-1-pegcetacoplan-in-combination-with-modified-folfirinox-for-the-treatment-of-metastatic-pancreatic-ductal-adenocarcinoma-100609416","NCT07214298","Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma","A Phase I\u002FII Study of Complement Inhibition in Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\n* Histologically or cytologically confirmed metastatic PDAC\n* Age ≥ 18 years of age\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1\n* Absolute neutrophil count ≥ 1,500\u002FuL\n* Platelets ≥ 100,000\u002FuL\n* Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)\n* Aspartate aminotransferase (AST)(serum oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT)(serum glutamic pyruvic transaminase \\[SGPT\\]) ≤ 3 x institutional ULN or \\\u003C=5 ULN in the presence of liver metastasis\n* Estimated creatinine clearance ≥ 60 mL\u002Fmin (Cockcroft-Gault equation)\n* Albumin ≥ 3 g\u002FdL\n* Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present\n* All patients must either have available archival tumor tissue or undergo new tumor biopsy (if presence of a lesion that can be safely biopsied) before treatment initiation for correlative studies\n* Willing and able to self-administer pegcetacoplan (administration by caregiver will be allowed)\n* Willing to receive vaccination against Neisseria meningitidis and Streptococcus pneumoniae if not already vaccinated\n* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n\n  * Women of child-bearing potential taking part in this study should continue the use of birth control for 6 months after the last study treatment, and should not donate eggs during that timeframe\n  * Male participants taking part in this study should continue the use of birth control for 3 months after the last study treatment, and should not donate sperm during that timeframe\n* Participant must understand the investigational nature of this study and sign an independent ethics committee\u002Finstitutional review board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Previous chemotherapy for PDAC. Gemcitabine-based post- or pre-operative therapy is allowed provided that the last dose and or surgical resection was at least 6 months prior to the documentation of metastatic disease, whichever occurred last\n* Toxicities from prior treatment grade \\> 1 with the exemption of alopecia and fatigue\n* Refractory ascites or pleural effusion (requiring para- or thoracentesis weekly or more frequently or use of indwelling catheter for palliation)\n* Untreated bowel or gastric outlet obstruction; patients with ≤ 6 weeks from such an event who are adequately palliated are allowed to participate\n* Participants with known untreated brain metastases will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Patients with major arterial thromboembolism (ATE) (coronary, cerebral, extremity or splanchnic) or venous thromboembolism (VTE) (pulmonary embolism or deep venous thrombosis) within 6 months from initiation of study treatment are not eligible for participation\n* Pregnant or nursing female participants\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug",{"count":116,"type":22},35,[72,73],"This phase I\u002FII trial tests the effect of pegcetacoplan in combination with oxaliplatin, irinotecan, leucovorin, and fluorouracil (mFOLFIRINOX) in treating patients with pancreatic ductal adenocarcinoma (PDAC) that has spread from where it first started (primary site) to other places in the body (metastatic). Pegcetacoplan works by targeting the immune complement process, a part of the immune system that defends against bacteria and may limit tumor progression and improve the immune system's response against tumor cells. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. Irinotecan is in a class of antineoplastic medications called topoisomerase I inhibitors. It blocks a certain enzyme needed for cell division and DNA repair and may kill tumor cells. Leucovorin is a drug used to lessen the toxic effects of substances that block the action of folic acid. Leucovorin is a form of folic acid. It is a type of chemoprotective agent and a type of chemosensitizing agent. Fluorouracil stops cells from making DNA and it may kill tumor cells. It is a type of antimetabolite. Giving pegcetacoplan in combination with mFOLFIRINOX may be safe, tolerable, and\u002For effecting in treating patients with metastatic PDAC. This trial also evaluates the effect of pegcetacoplan on the incidence of major thrombotic events and the resulting complications. Thrombosis is a common complication in patients with PDAC. Thrombosis occurs when blood clots block veins or arteries. Complications of thrombosis, such as stroke or heart attack, can be life-threatening. Giving pegcetacoplan may help prevent blood clots from forming and decrease the risk of major thrombotic events.",[120,121],"Metastatic Pancreatic Ductal Adenocarcinoma","Stage IV Pancreatic Cancer AJCC v8",{"date":123,"type":33},"2026-08-19",{"date":125,"type":33},"2026-02-16",{"date":127,"type":22},"2028-10-01",{"name":39,"class":40},{"id":130,"slug":131,"hasResults":12,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":12,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":41},"100594314","phase-2-gt103-in-combination-with-pembrolizumab-for-the-treatment-of-advanced-or-metastatic-stk11-mutant-non-small-cell-lung-cancer-100594314","NCT07017829","GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer","A Phase II Trial of GT103 in Combination With Pembrolizumab in STK11 Mutant Non-Small Cell Lung Cancer (NSCLC)","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 at the time of study treatment initiation.\n* Have pathologically confirmed diagnosis of STK11 mutant NSCLC. STK11 mutation will be based on subject's local clinically accredited laboratory testing (Clinical Laboratory Improvement Amendments \\[CLIA\\]-certified) using deoxyribonucleic acid (DNA) sequencing test.\n* Must have progressed on a pembrolizumab containing regimen and eligible for continuing pembrolizumab post-progression as determined by treating physician. Other anti-PD-1 or anti-PD-L1 checkpoint inhibitors may also be used in place of pembrolizumab\n* Adequate bone marrow and organ function as defined by the following lab values:\n* Absolute neutrophil count (ANC) ≥ 1.5 x 10\\^9\u002FL.\n* Platelets ≥ 100 x 10\\^9\u002FL.\n* Hemoglobin ≥ 9 g\u002FdL.\n* Estimated glomerular filtration rate (GFR) (measured or calculated with Cockroft and Gault formula) \\> 45mL\u002Fmin.\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN) (ALT and AST ≤ 5 x ULN is acceptable if liver metastases are present).\n* Total bilirubin ≤ 1.5 x ULN. For patients with well documented Gilbert's syndrome, total bilirubin ≤ 3 x ULN with direct bilirubin within normal range.\n* Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (LLN) (institutional limit).\n* Patients must have measurable disease as defined in Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\n* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure.\n* Participant agrees to provide blood samples at the start of treatment and at multiple times during the study. Participant agrees to provide tumor biopsy tissue or have adequate archival formalin-fixed paraffin-embedded (FFPE) tissue available.\n\nExclusion Criteria:\n\n* Receipt of anticancer chemotherapy within 4 weeks before the first administration of study drug.\n* Prior radiotherapy or gamma knife within 2 weeks of study treatment for non-brain metastasis. Subjects must have recovered from all radiation related toxicities.\n* Active\u002Funtreated brain metastasis. Whole brain radiation or gamma knife radiosurgery performed less than 4 weeks prior to first administration of study drug. Previously treated brain metastasis allowed as long as not requiring steroids and stable on imaging at least 4 weeks after completing radiation therapy.\n* Leptomeningeal involvement regardless of treatment status.\n* Tumor with oncogenic mutation based on standard of care broad genomic profiling in EGFR, ALK, ROS1, RET, MET, or NTRK genes.\n* History of autoimmune disorder, with exception of patients with vitiligo or endocrine-related autoimmune conditions receiving appropriate hormonal supplementation who are eligible. Systemic use of immunosuppressant drugs such as steroids (except as hormone replacement therapy or short-course supportive medication such as chemotherapy or drug allergy, etc.), azathioprine, tacrolimus, cyclosporine, etc. within 4 weeks before the first administration of study drug.\n* Currently receiving or has received systemic corticosteroids within 4 weeks prior to starting study drug for management of brain metastases, or who have not fully recovered from side effects of such treatment. Steroids for endocrine replacement or receipt of short-course of steroids during the preceding 4 week period as supportive medication such as for drug allergy, anti-emetic, etc. is allowed.\n* Had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered major surgery) resulting from a prior surgery.\n* Has known immunosuppressive disease (e.g., HIV, AIDS or other immune depressing disease). Testing is not mandatory.\n* Active, clinically serious infections or other serious uncontrolled medical conditions.\n* Patient has known hypersensitivity to the components of the study drugs or any analogs.\n* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator, including, but not limited to:\n\n  * Myocardial infarction or arterial thromboembolic events within 6 months prior to baseline or severe or unstable angina, New York Heart Association (NYHA) Class III or IV disease.\n  * History of documented congestive heart failure (New York Heart Association functional classification III or IV) within 6 months prior to baseline.\n  * Uncontrolled hypertension (systolic blood pressure \\[SBP\\] \\> 160\u002Fdiastolic blood pressure \\[DBP\\] \\> 100 despite medical intervention).\n  * History of myocarditis of any etiology.\n  * History of ventricular arrhythmias.\n* Patients diagnosed with an invasive cancer within 2 years prior to starting protocol therapy with the following exceptions: non-melanoma skin cancers, in-situ cancers, and prostate cancer Gleason ≤ 6 (under surveillance or treated), early-stage node-negative estrogen receptor positive (ER+)\u002Fprogesterone receptor positive (PR+) breast cancer with Oncotype Dx score \\\u003C 25 not taking adjuvant hormonal therapy.\n* Pregnant or nursing female participants.\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug.\n* Unwilling or unable to follow protocol requirements.",{"count":137,"type":22},28,[73],"This phase II trial tests how well GT103 in combination with pembrolizumab works in treating patients with STK11 mutant non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). GT103 is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. GT103 targets the tumor cell-protein complement factor H found on some cancer cells and may provide specific anti-tumor activity that may help block the formation of growths that may become cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving GT103 in combination with pembrolizumab may kill more cancer cells and improve outcomes in patients with advanced or metastatic STK11 mutant non-small cell lung cancer.",[141,142,143,144],"Advanced Lung Non-Small Cell Carcinoma","Metastatic Lung Non-Small Cell Carcinoma","Stage III Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8",{"date":123,"type":33},{"date":147,"type":33},"2026-04-01",{"date":149,"type":22},"2028-12-01",{"name":39,"class":40},{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":17,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":41},"100568427","a-community-health-education-intervention-for-increasing-community-driven-actions-to-reduce-the-cancer-burden-in-western-new-york-100568427","NCT06681077","A Community Health Education Intervention for Increasing Community-driven Actions to Reduce the Cancer Burden in Western New York","I Can Join the Fight Against Cancer: An Intervention to Programmatically Build Grassroots Actions to Reduce the Cancer Burden","Inclusion Criteria:\n\n* Being over 18 years old\n* Able to participate in English\n\nExclusion Criteria:\n\n* Unwilling or unable to follow protocol requirements",{"count":159,"type":22},500,[25],"This clinical trial evaluates a community health education intervention (I CAN) for increasing community-driven actions to reduce the cancer burden in Western New York. Engaging community members is a critical component of designing impactful programs to reduce the cancer burden. Leaders at the national, state, and local levels have all called for more community partnerships and engagement in design of health intervention and policies. The I CAN intervention is a workshop that includes a presentation outlining key concepts related to social network processes and the cancer burden in Western New York, a structured skill-building activity, and then empowering and motivating activities meant to cultivate momentum and excitement for action. This community health education intervention may be able to provide a formalized process for empowering and facilitating community members to take steps to reduce the community cancer burden.",[163],"Healthy",{"date":30,"type":33},{"date":166,"type":33},"2024-11-16",{"date":168,"type":22},"2028-11-15",{"name":39,"class":40},{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":179,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":41},"100592598","phase-2-olanzapine-for-managing-anorexia-in-head-and-neck-cancer-patients-undergoing-chemoradiation-macro-trial-100592598","NCT06995508","Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial","Managing Anorexia During Chemoradiation With Olanzapine (MACRO)","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2\n* Diagnosed with biopsy-proven, squamous cell carcinoma of the head and neck, including squamous cell carcinoma of the neck with unknown primary site\n* Eligible for curative-intent chemoradiation therapy of the head and neck\n* Patients must be eligible for concurrent systemic therapy (preferably platinum based) as determined by the treating medical oncologist to undergo platinum-based chemotherapy\n* Ability to swallow and retain oral medication\n* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Participants must agree to avoid the following while taking Olanzapine while they are on study:\n\n  * Taking the drug Symbyax (which already contains olanzapine)\n  * Consuming alcohol\n  * Operating hazardous machinery, including automobiles, until you are reasonably certain that the study drug therapy does not have any bad effects on your mental and physical health\n* Participant must understand the investigational nature of this study and sign an institutional review board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Eligible for palliative-intent radiation therapy only\n* Patients with a feeding tube\n* Regular systemic steroid use\n* Atypical antipsychotic use\n\n  * Other dopamine receptor blockers routinely used as anti-emetics (eg. prochlorperazine\u002Fcompazine and metoclopramide) are allowed to be prescribed as usual care on this study\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Known hypersensitivity to olanzapine\n* Pregnant or nursing female participants\n* Known history of seizures\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug",{"count":178,"type":22},66,[73],"This phase II trial compares the effect of adding olanzapine to standard of care symptom management for nausea to standard of care alone in managing an abnormal loss of the appetite for food (anorexia) in patients treated with chemoradiation therapy (CRT) for head and neck cancer. Patients undergoing CRT may experience treatment-related side effects, including pain, nausea, and a discomfort in the ability to speak, swallow and eat. These side effects have been shown to increase weight loss, opiate use and hospitalization. Olanzapine is a drug used to treat certain mental disorders. It is also being studied in the treatment of nausea and vomiting caused by some cancer treatments. It is a type of anti-psychotic and a type of monoamine antagonist. Adding olanzapine to standard of care symptom management to limit nausea may be more effective than standard of care alone in managing anorexia in head and neck cancer patients during CRT.",[182,183,184],"Cancer-Associated Anorexia","Head and Neck Squamous Cell Carcinoma","Neck Squamous Cell Carcinoma of Unknown Primary","2026-08-17",{"date":101,"type":33},{"date":188,"type":33},"2025-12-24",{"date":190,"type":22},"2031-11-15",{"name":39,"class":40},{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":12,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":41},"100564328","phase-2-mezigdomide-carfilzomib-and-dexamethasone-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma-in-patients-with-extramedullary-disease-100564328","NCT06627751","Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease","Phase II Clinical Trial of Mezigdomide\u002FCarfilzomib\u002FDexamethasone (MeziKD) in Patients With Relapsed or Refractory Multiple Myeloma (MM) With Extramedullary Disease (EMD)","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2\n* RRMM patients with one or more prior lines of therapy with at least one ES or PS lesion that is accessible to a biopsy. Accessibility will be assessed by the MM tumor board\n* Measurable disease meeting at least one of the following:\n\n  * Serum M-protein ≥1 g\u002FdL\n  * Urine M-protein ≥200 mg\u002F24 h\n  * Serum FLC assay: involved FLC level ≥10 mg\u002FdL provided serum FLC ratio is abnormal\n  * Up to 10 patients without measurable disease can be enrolled but screening imaging and\u002For bone marrow biopsy have to confirm RRMM. Follow-up response assessment will be performed with imaging using RECIST 1.1 and Deauville Criteria and bone marrow biopsies\n* Absolute neutrophil count: ≥ 1 x 10\\^9\u002FL\n* Platelets: ≥ 75 x 10\\^9\u002FL\n* Total bilirubin: ≤ 1.5 x upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]): ≤ 3 x ULN\n* Renal function: Estimated creatinine clearance ≥ 30 mL\u002Fmin (Cockroft-Gault)\n* Adequate cardiac pump function with a left ventricular ejection fraction of ≥ 40%\n* Women of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for at least 28 days after the last dose of mezigdomide or 6 months after the last dose of carfilzomib. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Male patients (non-vasectomized) must agree to use contraception during the treatment period and for at least 28 days after the last dose of mezigdomide or 3 months after the last dose of carfilzomib and refrain from donating sperm during this period\n* Participant must understand the investigational nature of this study and sign an independent ethics committee\u002Finstitutional review board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Participant has a history of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, pomalidomide (including ≥ grade 3 rash during prior thalidomide, lenalidomide, or pomalidomide therapy), carfilzomib or dexamethasone, any cereblon E3 ligase modulators (CELMoD) agents, or the excipients contained in the formulations, or participant has any contraindications per local prescribing information\n* Administration of strong CYP3A modulators or proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole) within 2 weeks of starting study intervention\n* Participant is unable or unwilling to undergo protocol required thromboembolism prophylaxis\n* Patient has evidence of mucosal or internal bleeding and\u002For is platelet transfusion refractory\n* Any medical conditions that, in the investigator's opinion, would impose excessive risk to the patient or would adversely affect his\u002Fher participation in this study\n* Known active infection requiring parenteral or oral anti-infective treatment within the past 14 days\n* Participant has a history of prior malignancy other than MM, except if the participant has been free of disease for ≥ 3 years or the participant had 1 of the following noninvasive malignancies treated with curative intent without known recurrence:\n\n  * Basal or squamous cell carcinoma of the skin\n  * Carcinoma in situ of the cervix or breast\n  * Stage 1 bladder cancer\n  * Incidental histological findings of localized prostate cancer such as tumor stage 1a or 1b (T1a or T1b) using the tumor, nodes, and metastasis (TNM) classification of malignant tumors OR prostate cancer that has been treated with curative intent\n* Other ongoing anti-myeloma therapy. Patients may be receiving concomitant therapy with bisphosphonates and low dose corticosteroids for symptom management and comorbid conditions. Doses of corticosteroid should be stable for at least 7 days prior to patient registration\n* Pregnant or breast-feeding females\n* Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or confuse follow-up evaluation\n* Known active HIV or hepatitis B or C viral infection\n* Known history of HIV infection\n* Systemic amyloidosis or POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein \\[M-protein\\] and skin changes)\n* Prior peripheral stem cell transplant within 12 weeks of study enrollment\n* Radiotherapy within 14 days prior to cycle 1 day 1. However, if the radiation portal covered ≤ 5% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy\n* Known intolerance to steroid therapy\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, severe cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Carfilzomib-refractory in the most recent line of therapy\n* Prior treatment with mezigdomide\n* Contraindication against conscious sedation\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug",{"count":137,"type":22},[73],"This phase II trial studies how well mezigdomide\u002Fcarfilzomib\u002Fdexamethasone (MeziKD) works in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and have tumors from myeloma cells outside the bone marrow in the soft tissues or organs of the body (extramedullary disease \\[EMD\\]). Mezigdomide blocks important processes in myeloma cells and may lead to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dexamethasone is a type of corticosteroid and is used to kill myeloma cells. It is used with other drugs to treat multiple myeloma. Giving MeziKD may kill more cancer cells in patients with relapsed\u002Frefractory multiple myeloma (RRMM) with EMD.",[203,204,205],"Extramedullary Disease in Multiple Myeloma","Recurrent Multiple Myeloma","Refractory Multiple Myeloma",{"date":101,"type":33},{"date":208,"type":33},"2025-05-01",{"date":210,"type":22},"2030-05-01",{"name":39,"class":40},{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":18,"minAge":219,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":23,"phases":222,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":41},"100499790","home-based-respiratory-muscle-training-for-minimizing-side-effects-in-patients-undergoing-treatment-for-cancer-100499790","NCT05787834","Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Cancer","Respiratory Muscle Training During Cancer Treatment: Effects on the Autonomic Nervous System and Cardiotoxicity","Inclusion Criteria:\n\n* Able and willing to provide written informed consent\n* Age \\>= 21 years old\n* Diagnosed with solid tumor (e.g., head and neck, thoracic, or breast cancer)\n* Scheduled to receive at least one dose of chemotherapy or immunotherapy or radiation\n* Treated at Roswell Park Comprehensive Cancer Center\n\nExclusion Criteria:\n\n* Presence of oral mucosal disease including oral mucositis, or oral candidiasis detected at baseline\n* Have uncontrolled intercurrent illness including, but not limited to, ongoing or active respiratory infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, heart failure or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study intervention","21 Years",{"count":221,"type":22},130,[25],"This clinical trial evaluates whether home-based respiratory muscle training is useful for minimizing side effects in patients undergoing treatment for cancer. Over-activation of the nervous system during breast cancer treatment can result in heart- and lung-related side effects which have the potential to reduce a patient's quality of life. Aerobic exercise can help prevent the development of these side effects. However, engaging in regular aerobic exercise may be difficult for breast cancer patients who are actively undergoing treatment. Respiratory muscle training (RMT) involves a series of breathing and other exercises that are performed to improve the function of the respiratory muscles through resistance and endurance training. Home-based RMT may represent a more feasible approach for reducing side effects in patients undergoing treatment for breast cancer.",[225,226,227],"Breast Carcinoma","Head and Neck Cancer","Lung Cancer",{"date":123,"type":33},{"date":230,"type":33},"2023-10-16",{"date":232,"type":22},"2029-10-16",{"name":39,"class":40},{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":18,"minAge":48,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":243,"phases":4,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":41},"100626733","understanding-tobacco-and-cannabis-co-use-practices-initiation-escalation-and-maintenance-100626733","NCT07439471","Understanding Tobacco and Cannabis Co-Use Practices: Initiation, Escalation, and Maintenance","Inclusion Criteria:\n\n* \\* Adults aged 18 to 30 years old.\n\n  * Currently living in the Roswell Park catchment area.\n  * Able to speak, read, and write in English.\n  * Currently consuming cannabis at least weekly.\n\n    * Group 1: currently using cigarettes daily and not using nicotine vaping products more than one day per week.\n    * Group 2: currently using nicotine vaping products daily and not using cigarettes more than one day per week.\n\nExclusion Criteria:\n\n* \\* Unwilling or unable to follow protocol requirements.\n\n  * Individuals under the age of 18 or over 30.\n  * Individuals not meeting product consumption criteria for inclusion items 3 and 4.","30 Years",{"count":242,"type":22},40,"OBSERVATIONAL","This study evaluates histories among cannabis and tobacco co-users of their initiation, escalation, and maintenance of the co-use behavior.",[246],"Cigarette Smoking-Related Carcinoma","2026-08-14",{"date":185,"type":33},{"date":250,"type":22},"2026-09-28",{"date":252,"type":22},"2027-03",{"name":39,"class":40},{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":41},"100583060","phase-1-genetically-engineered-cells-cd83-car-t-cells-for-the-treatment-of-relapsed-or-refractory-acute-myeloid-leukemia-100583060","NCT06871410","Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","CD83 CAR T in Relapsed or Refractory Acute Myeloid Leukemia (AML): A Phase I Trial","Inclusion Criteria:\n\n* Age ≥ 18 years old.\n* Karnofsky performance status score ≥ 70%.\n* Relapsed or refractory AML based upon ELN 2022 criteria.\n* Creatinine clearance: ≥ 40 mL\u002Fmin (Cockroft-Gault).\n* Total bilirubin: ≤ 2mg\u002FdL except for patients with Gilbert's syndrome, hemolysis, or related to disease.\n* Aspartate aminotransferase (AST) and alanine transaminase (ALT) \\\u003C 3.0 x upper limit of normal (ULN).\n* Left ventricular (LV) ejection fraction: \\> 45% and be free of symptomatic congestive heart failure or uncontrolled arrhythmia.\n* Oxygen (O2) saturation: ≥ 92% on room air without needs for supplemental O2.\n* Absolute lymphocyte count: ≥ 0.2 x 10\\^9\u002FL, HCT of ≥ 27% and platelets of ≥ 20 x 10\\^9\u002FL. Transfusion support is allowed to meet HCT and platelet parameters prior to apheresis.\n* Life expectancy ≥12 weeks from the time of enrollment, per clinical judgment.\n* Negative serum pregnancy test in females of child-bearing potential (FOCBP). FOCBP is defined as any female who has experienced menarche and who has not undergone successful surgical sterilization or who is not postmenopausal.\n* If history of allogeneic HCT, must have completed transplant at least 3 months prior, be off immunosuppression, including ruxolitinib, at least 2 weeks prior to apheresis, and have no evidence of GVHD requiring treatment at enrollment.\n* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for 12 months following duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n* Participants must be considered preliminarily eligible for an allogeneic hematopoietic cell transplantation, with potential donors identified per a transplant and cellular therapy consult at Roswell Park Comprehensive Cancer Center.\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure.\n\nExclusion Criteria:\n\n* Concomitant systemic glucocorticoid use at a dose equivalent to \\> 10 mg daily prednisone at the time of apheresis and\u002For within 4 weeks of CD83 CAR T infusion for any reasons other than GVHD.\n* Diagnosis of acute promyelocytic leukemia (APL; AML M3 by French-American-British \\[FAB\\] classification).\n* Active central nervous system (CNS) leukemia; patients with history of CNS leukemia in complete response (CR) are eligible.\n* Patients enrolled in another investigational therapy protocol for their disease within 14 days or 5 half-lives prior to leukapheresis, whichever is shorter.\n* Patients requiring agents or any treatments other than hydroxyurea, single agent cytarbine,hypomethylating agents with or without ventoclax and\u002For targeted agents (i.e., FLT3, IDH2 or IDH1 inhibitors) to control blast counts within 14 days or 5 half-lives (whichever is shorter) prior to lymphodepletion.\n* Ongoing uncontrolled serious infection, pulmonary disease or psycho\u002Fsocial concerns.\n* HIV seropositivity or active hepatitis B or C infection within (defined by positive polymerase chain reaction \\[PCR\\]) 4 weeks of enrollment.\n* Other active malignancy within 2 years of study entry, except for basal cell cancer of skin, cervical cancer treated surgically with curative intent or localized prostate cancer managed with observational approach.\n* Active grade II-IV acute GVHD in patients with relapsed AML after HCT requiring treatment.\n* Prior solid organ transplant.\n* Active autoimmune disease requiring immunosuppressive therapy.\n* Pregnant or nursing female participants.\n* Unwilling or unable to follow protocol requirements.\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug.",{"count":262,"type":22},26,[72],"This phase I trial tests the safety, side effects, and best dose of genetically engineered cells (CD83 chimeric antigen receptor \\[CAR\\] T cells) in treating patients with acute myeloid leukemia (AML) that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). CD83 is a protein that is found on AML blasts. Blasts are abnormal immature white blood cells that can multiply uncontrollably: filling up the bone marrow and preventing the production of other cells important for survival. CD83 CAR T cells represent a new cell therapy to eliminate AML blasts, while avoiding the risk for graft versus host disease (GVHD) after stem cell transplant to replace bone marrow or, tumor toxicity like myeloid aplasia where the body's own immune system causes damage to the bone marrow stem cells. Therefore, human CD83 CAR T cells are a promising cell-based approach to preventing two critical complications of stem-cell transplant - GVHD and relapse. Giving CD83 CAR T cells may be safe, tolerable, and\u002For effective in treating patients with relapsed or refractory AML.",[266,267],"Recurrent Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia",{"date":185,"type":33},{"date":270,"type":33},"2026-02-02",{"date":272,"type":22},"2028-04-01",{"name":39,"class":40},{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":23,"phases":283,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":41},"100563887","phase-1-sx-682-in-combination-with-carfilzomib-daratumumab-hyaluronidase-and-dexamethasone-in-patients-with-relapsed-or-refractory-multiple-myeloma-100563887","NCT06622005","SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","Phase 1 Trial of SX-682, a CXCR 1\u002F2 Inhibitor, in Combination With Standard of Care Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)","Inclusion Criteria:\n\n* Confirmed relapsed\u002F refractory multiple myeloma\n* Measurable disease including at least one of the following criteria:\n\n  * Serum M-protein ≥ 0.5 g\u002FdL\n  * Urine M-protein ≥ 200 mg\u002F24h\n  * Serum free light chain assay: involved free light chain (FLC) level greater or equal to 100 mg\u002FL provided serum free light chain ratio is abnormal\n  * Bone marrow plasma cells ≥ 10% total bone marrow cells\n* ≥ 1 prior line of therapy\n* Planned treatment with a carfilzomib\u002Fdaratumumab\u002Fdexamethasone regimen\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Absolute neutrophil count: ≥ 1.5 x 10\\^9\u002FL\n* Platelets: ≥ 75 x 10\\^9\u002FL\n* Hemoglobin: ≥ 7 g\u002FdL\n* Total bilirubin: ≤ 1.5 x upper limit of normal (ULN): ≤ 3.0 x ULN for Gilbert's syndrome\n* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \\[SGOT\\]) \u002F alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase \\[SGPT\\]): ≤ 3 x ULN\n* Renal Function: Estimated creatinine clearance ≥ 45 mL\u002Fmin (Cockroft-Gault)\n* Left ventricular ejection fraction of at least 50%\n* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for 6 months following the last dose of the investigational drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Participant must understand the investigational nature of this study and sign an Independent ethics committee\u002Finstitutional review board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Patients with non-secretory myeloma, systemic light chain amyloidosis or, plasmacytoma\n* Intolerance to SX-682 or any other of the treatment components\n* Refractory to prior carfilzomib (i.e. relapse or progression on or within 60 days after completion of treatment)\n* Refractory to prior daratumumab (i.e. relapse or progression on or within 60 days after completion of treatment)\n* Concomitant medication(s) known to be (a) a strong inhibitor or inducer of CYP3A4, or (b) QT prolonging as defined in the drug's approved label, with the exception of drugs that are considered absolutely essential for the care of the subject or if the investigator believes that beginning therapy with such medication is vital to an individual subject's care while on study, and in either case, there is no alternative medication\n* Electrocardiogram (ECG) demonstrating a corrected QT (QTc) interval \\> 470 msec or patients with congenital long QT syndrome\n* Coronary artery bypass, angioplasty, vascular stent, myocardial infarction, angina or congestive heart failure in the last 6 months\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, class III or IV heart failure (New York Heart Association functional classification system) or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* History of hepatitis B, C or HIV\n* Known active bacillus tuberculosis infection\n* Pregnant or nursing female participants\n* Unwilling or unable to follow protocol requirements\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug",{"count":282,"type":22},15,[72],"This phase I trial tests the safety and side effects of SX-682 in combination with standard of care treatment carfilzomib, daratumumab-hyaluronidase, and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). SX-682 works by blocking certain sites on cells that suppress the ability of the immune system to destroy tumor cells. Blocking those specific sites allows other cells of the immune system to become \"free\" to kill tumor cells. Carfilzomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and tumor cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill tumor cells, while hyaluronidase helps to deliver daratumumab to CD38-expressing tumor cells through a subcutaneous injection. Dexamethasone is in a class of medications called corticosteroids. It is known to kill myeloma cells and is also used to reduce inflammation and lower the body's immune response to monoclonal antibodies like dratumumab and help lessen its side effects. Giving SX-682 in combination with carfilzomib, daratumumab-hyaluronidase and dexamethasone may be safe and tolerable in treating patients with relapsed or refractory multiple myeloma",[204,205],"2026-08-12",{"date":288,"type":33},"2026-08-13",{"date":290,"type":33},"2025-04-10",{"date":292,"type":22},"2030-04-10",{"name":39,"class":40},{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":301,"minAge":48,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":23,"phases":304,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":328},"100457017","phase-2-pembrolizumab-combined-with-bevacizumab-with-or-without-agonist-anti-cd40-cdx-1140-for-the-treatment-of-patients-with-recurrent-ovarian-cancer-100457017","NCT05231122","Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer","Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer","Inclusion Criteria:\n\n* Age \\>= 18 years of age.\n* Recurrent serous (low grade or high grade), endometrioid, or clear cell recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.\n* Participant can be either platinum-sensitive or platinum-resistant, no more than 4 prior lines of treatment, and BRCA status must be known.\n\nNeoadjuvant + adjuvant is considered one line.\n\n* Participants may have received a prior PARPi, this will not be considered a separate line of therapy if received in maintenance.\n* Participants may have received a prior anti-PD1\u002Fanti-PDL1 therapy or bevacizumab, these will not be considered a separate line of therapy.\n* Any chemotherapy regimen change due to toxicity in the absence of disease progression will be considered part of the same line of therapy.\n* Hormonal therapy for OC (e.g. Tamoxifen, aromatase inhibitors etc.) will not count as a separate line of prior therapy.\n\n  * Anticipated lifespan greater than 6 months.\n  * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n  * Patient has measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present.\n  * All residual toxicity related to prior anti-cancer therapies (excluding alopecia, grade 2 fatigue, vitiligo, endocrinopathies on stable replacement therapy, grade 2 neuropathy from taxanes or platinum and grade 2 hearing loss from platinum) must be resolved to grade 1 severity or less (or returned to baseline) prior to receipt of study treatment.\n  * Absolute neutrophil count (ANC): \\>= 1,500 \u002FmcL.\n  * Platelets: \\>= 100,000 \u002F mcL.\n  * Hemoglobin: \\>= 8 g\u002FdL or 5.0 mmol\u002FL transfusion allowed with adequate bone marrow function\n  * Creatinine clearance \\>= 50 mL\u002Fmin.\n  * Total bilirubin: =\\\u003C 2 X upper limit of normal (ULN) except patients with Gilbert's syndrome or liver involvement, who must have a total bilirubin =\\\u003C 3 mg\u002FdL.\n  * Aspartate aminotransferase (AST) ( serum glutamic-oxaloacetic transaminase \\[SGOT\\] ) and alanine aminotransferase (ALT) ( serum glutamate pyruvate transaminase \\[SGPT\\]): =\\\u003C 2.5 X ULN OR =\\\u003C 5 X ULN for participants with liver metastases.\n  * Albumin: \\> 2.5 mg\u002FdL.\n  * International normalized ratio (INR) OR prothrombin time (PT) activated partial thromboplastin time (APTT) =\\\u003C 1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants.\n  * Participant must be willing to undergo core or excisional biopsy of a tumor lesion within 7 days prior to the first dose of investigational product and after 3 cycles of treatment(prior to cycle 4-day 1: mandatory only if available) and, at the end of treatment (optional). Participants for whom newly obtained samples cannot be provided at baseline (e.g., inaccessible or subject safety concern), may submit an archived specimen, only upon agreement from the Prinicipal Investigator, if available).\n  * A woman of childbearing potential must have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n  * Participants of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity for the course of the study through 6 months after the last dose of study medication (participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \\> 1 year). Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.\n  * Participant (or legal representative) must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure.\n\nExclusion Criteria:\n\n* Primary platinum-refractory patients are excluded\n* Has a nonepithelial cancer (germ cell tumors, sex cord-stromal tumors), borderline tumors, mucinous or seromucinous that is predominately mucinous, malignant Brenner's tumor, carcinosarcoma or undifferentiated carcinoma.\n* Receipt of any antibody targeting T cell checkpoint or co-stimulation pathways within 4 weeks, use of any other monoclonal based therapies within 4 weeks, and all other immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) within 2 weeks prior to the planned start of study treatment.\n* Has received prior systemic anticancer therapy (including investigational agents or maintenance therapy) within 28 days prior to the planned start of study treatment.\n\nHormonal therapy is allowed until the time of randomization\n\n* Progression on prior immune checkpoint blockade therapy.\n* Systemic radiation therapy within 4 weeks, prior focal radiotherapy within 2 weeks prior to the first dose of study treatment.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug\n* Major surgery within 4 weeks prior to the first dose of study treatment. Surgery requiring local\u002Fepidural anesthesia must be completed at least 72 hours before study drug administration and patients should be recovered.\n* Known or prior malignancy requiring active treatment in the past 2 years. Exception: basal or squamous cell skin cancer or in situ cancers; or any other cancer from which the patient has been disease-free for at least 3 years.\n* Active, untreated central nervous system metastases. Patients with brain metastases identified at screening may be rescreened after the lesion(s) have been appropriately treated; patients with treated brain metastases should be neurologically stable for 4 weeks post-treatment and prior to study enrollment, and off corticosteroids for at least 2 weeks before administration of study drugs, and treated lesions should demonstrate no new growth on the re-screening scan.\n* History of (non-infectious) pneumonitis or has current pneumonitis, including grade 1 (asymptomatic; clinical or diagnostic observations only; intervention not indicated) pneumonitis.\n* History of severe hypersensitivity reactions to other monoclonal antibodies (mAbs).\n* Prior therapy with any anti-CD40 antibody.\n* Hypersensitivity to bevacizumab, pembrolizumab, or any of its excipients.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid)\n* Known active or chronic viral hepatitis or history of any type of hepatitis within the last 6 months.\n* Has an acute infection requiring systemic therapy\n* Known immunodeficiency or active human immunodeficiency virus (HIV)\n* Concurrent active Hepatitis B (defined as HBsAg positive and\u002For detectable HBV DNA)and Hepatitis C virus (defined as anti-HCV Ab positive and detectable HCV RNA) infection. Note: Hepatitis B and C screening tests are not required unless known history of HBV and HCV infection\n* Has an active infection requiring systemic therapy\n* Known immunodeficiency or active HIV\n* Has received any investigational vaccines (i.e., those not licensed or approved for emergency use). Note: Any licensed COVID-19 vaccine (including for Emergency Use) is allowed in the study as long as they are mRNA vaccines, adenoviral vaccines, or inactivated vaccines. These vaccines will be treated just as any other concomitant therapy.\n\nInvestigational vaccines (i.e., those not licensed or approved for Emergency Use) are not allowed.\n\n* Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.\n* Subject requires or is likely to require more than a two-week course of corticosteroids for intercurrent illness. Subject must complete the course of corticosteroids 2 weeks before screening to meet eligibility.\n* Subject has a serious, non-healing wound, ulcer, or bone fracture.\n* Subject has a clinically significant cardiovascular disease including:\n\n  * Uncontrolled hypertension \\\u003C 150\u002F90 mmHg (may be rescreened after adequate control)\n  * Myocardial infarction or unstable angina within 6 months prior to enrollment\n  * New York Heart Association (NYHA) Grade II or greater congestive heart failure.\n* New onset on thromboembolic event or hemorrhage within 6 weeks prior to randomization\n* Subject has organ allografts.\n* Subject has clinical symptoms or signs of partial or complete gastrointestinal obstruction or require parenteral hydration and\u002For nutrition.\n* Pregnant or nursing female participants.\n* Known active alcohol or drug abuse.\n* Unwilling or unable to follow protocol requirements.\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug.","FEMALE",{"count":303,"type":22},80,[73],"This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent). Anti-CD40 CDX-1140 works by stimulating certain immune cells within the tumor and, when combined with other immunotherapy treatments, may increase antitumor antibody production. Immunotherapy with monoclonal antibodies, such as pembrolizumab and bevacizumab, may help the body's immune system, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and bevacizumab with anti-CD40 CDX-1140 may decrease symptoms, prolong survival, and improve quality of life in patients with ovarian cancer.",[307,308,309,310,311,312,313,314,315,316,317,318,319,320,321],"Ovarian Clear Cell Adenocarcinoma","Platinum-Sensitive Ovarian Carcinoma","Recurrent Endometrial Serous Adenocarcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Fallopian Tube Endometrioid Adenocarcinoma","Recurrent Fallopian Tube Serous Adenocarcinoma","Recurrent Ovarian Carcinoma","Recurrent Ovarian Clear Cell Adenocarcinoma","Recurrent Ovarian Endometrioid Adenocarcinoma","Recurrent Ovarian Serous Adenocarcinoma","Recurrent Platinum-Resistant Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Recurrent Primary Peritoneal Clear Cell Adenocarcinoma","Recurrent Primary Peritoneal Endometrioid Adenocarcinoma","Recurrent Primary Peritoneal Serous Adenocarcinoma",{"date":247,"type":33},{"date":324,"type":33},"2024-03-12",{"date":326,"type":22},"2027-03-15",{"name":39,"class":40},2,{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":18,"minAge":48,"maxAge":336,"enrollmentInfo":337,"targetDuration":4,"studyType":23,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":346,"leadSponsor":348,"locationsCount":41},"100579650","phase-2-psilocybin-with-psychotherapy-for-improving-chronic-pain-in-cancer-patients-requiring-opioids-100579650","NCT06827054","Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids","Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring Opioids","Inclusion Criteria:\n\n* Age ≥ 18 and ≤ 75 years old\n* Diagnosis of active cancer, any stage\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Estimated prognosis of ≥ 3 months at the time of enrollment, determined by participant's primary oncologist or palliative physician\n* Diagnosis of moderate to severe pain (reported average pain score ≥ 4 on the 11-point Numerical Rating Scale) that is chronic (≥ 3 months) and secondary to cancer or cancer treatment\n* Pain regimen has been escalated to opioid therapy\n\n  * Participants must be on stable pain regimen for at least one month prior, with no intention to adjust pain regimen during the study period\n* Participants must be ≥ 4 weeks beyond treatments\u002Fprocedures that, in the opinion of the study physician, would significantly affect outcomes related to pain and physical function (e.g., surgery or radiation). Participants may otherwise receive cancer-directed treatment throughout the study period\n* Have no known procedures\u002Ftreatments scheduled in advance that would prohibit patient from completing or significantly delaying completion of the study\n\n  * The participant has no vacations or plans to be out of town during their study enrollment\n* Participants must not plan for additional treatments\u002Fprocedures that, in the opinion of the study physician, would significantly affect outcomes related to pain and physical function (e.g., surgery or radiation) for ≥ 4 weeks following psilocybin treatment initiation. Participants may otherwise receive cancer-directed treatment throughout the study period\n* No use of other illicit substances (excluding cannabis) within the past year based on self-report at screening and routine urine toxicology screen\n* Participants must be able to read, write, and speak English\n* Participants must be able to swallow pills\n* Agree to refrain from using any unprescribed psychoactive drugs, including alcoholic beverages, ≤ 24 hours of before each psilocybin administration. Exceptions include:\n\n  * Daily use of caffeine or nicotine\n  * Prescribed benzodiazepine medications and non-benzodiazepine sleeping medications will be allowed to continue through the study period for participants who have been on a stable dose of such a medicine for ≥ 6 weeks prior to screening\n* Participants using cannabis, including legal cannabis, for any purpose must agree to refrain from use beginning at two weeks before dosing and one week following completion of dosing (7-8 weeks total, dependent on frequency of prior use)\n\n  * Participants will not be withdrawn from the trial for a positive cannabis result during the initial screening drug test. However, participants who test positive for cannabis at the second drug test on visit 10 will be withdrawn from the trial\n* Participants must agree to be driven home after each experimental session and not drive or operate heavy machinery ≤ 16 hours of ingesting psilocybin\n* Participants must provide an emergency contact (relative, spouse, close friend, or other support person) willing and able to be reached by the investigators if the participant is unreachable by study staff or in an emergency\n* The participant agrees to take part in all study procedures, including the assessments, psychological evaluations, and dosing day requirements\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Participants who are pregnant or breast-feeding\n* Participants of childbearing potential who decline to use a highly effective dual contraceptive method for the duration of the study\n* Participants with a condition impairing oral intake or digestive absorption\n* Cognitive impairment as defined by Montreal Cognitive Assessment (MOCA) score \\\u003C 23\n* Medical conditions or serious abnormalities of complete blood count, chemistries, or electrocardiography (ECG) that in the opinion of the study physician would preclude safe participation in the trial. Some examples include: congestive heart failure, valvular heart disease, recent acute myocardial infarction or evidence of ischemia, clinically significant arrhythmias (e.g., ventricular fibrillation, torsades) or clinically significant ECG abnormality (e.g. corrected QT interval using Fridericia's Correction Formula \\[QTcF\\] interval \\> 450 in males and \\> 470 in females), uncontrolled hypertension (systolic blood pressure \\[BP\\] ≥ 140 or diastolic BP ≥ 90 on three separate occasions), congenital long QT syndrome, renal dysfunction (i.e. creatinine clearance \\[CrCl\\] \\\u003C 40 mL\u002Fmin), liver cirrhosis or hepatic dysfunction (indicated by gamma-glutamyltransferase \\[GGT\\], aspartate aminotransferase \\[AST\\], or alanine aminotransferase \\[ALT\\] \\> 3 x ULN \\[upper limit of norm\\] or total bilirubin \\[bili\\] \\> 3.0 mg\u002Fdl, or Child Pugh over class C), paraneoplastic syndrome, respiratory failure, dementia, delirium, known cerebral aneurysm, seizure disorder, stroke\u002Ftransient ischemic attack (TIA) in past year, cancer with known central nervous system (CNS) involvement, previously treated brain metastasis, or other major CNS disease\n* Participants who have a personal history of, or a current diagnosis of the following: primary psychotic disorder, major depressive disorder with psychotic features, bipolar affective disorder type 1 or history of or current dissociative identity disorder\n* Participants who have an ongoing substance use disorder (defined as active in the past year)\n* Participants with first-degree relatives with schizophrenia or bipolar disorder may be eligible depending on their age and personal and family psychiatric history. The decision will be made by the principal investigator and study psychiatrist or on-call psychiatric provider based on risk assessment\n* Active suicidal behavior (interrupted or aborted attempt; preparatory acts) as assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) connotating either passive or active suicidal intent; OR one of the following:\n\n  * History of suicide attempt(s) within the past year (≤ 365 days)\n  * Have any suicidal ideation or thoughts, in the opinion of the study physician or principal investigator (PI), that presents a serious risk of suicidal or self-injurious behavior\n* Any contraindications to undergoing an fMRI scan, including having metal implants or metal fragments in the body\n* Participants who have hypersensitivity to the ingredients of the IMP (Investigational Medicinal Product) listed below:\n\n  * Indol alkaloids including psilocybin and psilocin\n  * Constituents of Psilocybe cubensis including protein, fats, carbohydrates, ergosterols, beta-glucan, and polyphenols\n  * Hydroxypropyl methylcellulose (HPMC) capsules\n* Participants who are taking medications with significant potential to interact with study medications will be exclusionary if they cannot be tapered. The taper interval will be at least five times the half-life. These medications include the following:\n\n  * Selective serotonin reuptake inhibitors (SSRIs)\n  * Serotonin and norepinephrine reuptake inhibitors (SNRIs)\n  * Tricyclic antidepressants (TCAs)\n  * Efavirenz\n  * Serotonin-acting dietary supplements (i.e., 5-hydroxy-tryptophan or St. John's wort)\n  * Centrally acting serotonergic agents (e.g., monoamine oxidase \\[MAO\\] inhibitors)\n  * Antipsychotics for a psychiatric disorder (e.g., first and second generation)\n\n    * Antipsychotics that are utilized for nausea, insomnia, or other non-psychiatric condition will be permitted, but patients will be asked to refrain from use 8 hours prior to dosing sessions\n  * Mood stabilizers (e.g., lithium, valproic acid)\n  * Aldehyde dehydrogenase inhibitors (e.g., disulfiram)\n  * Significant inhibitors of UGT 1A9 or UGT 1A10\n* Use of serotonergic hallucinogens (e.g., psilocybin, lysergic acid diethylamine \\[LSD\\]) within the past 12 months or significant lifetime use (\\> 25 uses)\n* Those with a history of prior violent and\u002For drug-related felonies\n* Those currently incarcerated will be excluded\n* Unwilling or unable to follow protocol requirements\n* Any social circumstance which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug","75 Years",{"count":96,"type":22},[73],"This phase II trial studies whether psilocybin with psychotherapy is safe and if it works for improving chronic pain in cancer patients who require opioids to manage their pain. Psilocybin is taken from the mushroom Psilocybe mexicana. Psilocybin acts on the brain to cause hallucinations (sights, sounds, smells, tastes, or touches that a person believes to be real but are not real). This may impact a patient's \"total pain\", a view that accounts for the psychological, spiritual, and social factors that contribute to their experience of pain. Psychotherapy uses methods such as discussion, listening, and counseling to help patients change the way they react to environmental triggers that may cause a negative reaction. Giving psilocybin with psychotherapy may be safe and helpful for improving chronic pain in cancer patients who require opioids to manage their pain.",[341,342],"Hematopoietic and Lymphatic System Neoplasm","Malignant Solid Neoplasm","2026-08-10",{"date":286,"type":33},{"date":35,"type":22},{"date":347,"type":22},"2027-05-05",{"name":39,"class":40},{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":17,"sex":18,"minAge":219,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":23,"phases":358,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":365,"leadSponsor":367,"locationsCount":41},"100541757","early-phase-1-evaluating-the-delivery-and-effects-of-thc-vaping-liquids-in-the-bloodstream-100541757","NCT06334016","Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream","Acute Effects of Sequential Nicotine Vaping on the Pharmacokinetic and Pharmacodynamic Properties of Vaped THC: A Double-Blind, Placebo-Controlled, Randomized Within-Subject Crossover Study","Inclusion Criteria:\n\n* Age ≥ 21 years of age; (self-reported on screening, verified at study visit).\n* Report use of commercial THC vaping cartridges for at least 3 months prior to enrollment; (self-reported).\n* Experience with THC potency at or above the study product AND experience with chasing THC with nicotine (at least monthly); (self-reported).\n* Report use of THC vaping liquids at least weekly (4x\u002Fmonth); (self-reported).\n* Daily use of nicotine vaping products containing 5% nicotine for at least 3 months prior to enrollment; (self-reported).\n* Report of not currently trying to become pregnant (females). Women of childbearing potential must be willing to provide a urine sample and test negative prior to receiving any study-related products\u002Fprocedures.\n* Willing to complete a THC saliva test to check for recent use (NarcoCheck Ref#: NCE-STHC-1), semi-quantitative urinary THCA rapid test (NarcoCheck® THC Pre Dosage), and an illicit drug urine test (NarcoCheck® Évolutive®) during baseline testing, prior to receiving any study-related products.\n* Negative THC saliva test (NarcoCheck Ref#: NCE-S-THC-1), detection level 1-3 on urinary THCA rapid test (NarcoCheck® THC PreDosage), and illicit drug screen negative for all drugs except THC (NarcoCheck® Évolutive®).\n* Willing to abstain from nicotine use for 8 hours prior to each study session and abstain from cannabis use 7 days prior to each session.\n* Participant must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure.\n\nExclusion Criteria:\n\n* Detection level 4-5 (\\> 300 ng\u002FmL) on urinary THCA rapid test (NarcoCheck® THC PreDosage Ref#: DOA-M03-9B) and a positive result on THC saliva test (NarcoCheck Ref#: NCE-S-THC-1).\n* Illegal or non-prescription drug use within the past 90 days. As detected by NarcoCheck® Évolutive® (detection in human urine of the 12 most currently abused drugs) at the first session and prior to receiving any study product. THC use detected by NarcoCheck® Évolutive® is permitted\n* Illegal or non-prescription drug use\u002Falcohol substance use disorder (SUD) within the past year; (self-reported).\n* Report 2 or more drinking occasions\u002Fweek with 4 or more drinks\u002Foccasion; (self-reported).\n* Report of daily cigarette use; (self-reported).\n* Current or prior diagnosis of schizophrenia, bipolar disorder, or other severe psychotic mental illness; (self-reported).\n* Current or prior diagnosis of myocardial infarction, arrhythmia, or congestive heart failure (self-reported).\n* Current or prior cancer diagnosis.\n* Pregnant, currently trying to become pregnant, or breastfeeding (females); (self-reported; pregnancy validated on study visit by urine test).\n* Regular use of medications that contain nicotine, induce CYP2A6, stimulants, or sympatholytics (e.g., beta-blockers); (self-reported).\n* Unwilling or unable to follow protocol requirements.\n* Any condition which in the Investigator's opinion deems the participant an unsuitable candidate for participation.\n* The following special populations will be excluded:\n\n  * Cognitively impaired adults\u002Fadults with impaired decision-making capacity\n  * Individuals who are not yet adults (infants, children, teenagers)\n  * Pregnant women\n  * Prisoners\n* No children or person under the age of 21 will be involved in the study. While those under 21 may use cannabis smoked or vaping products, the legal age of purchasing and using those products in New York State is 21. The current legal age to purchase and use tobacco products in New York State (NYS) is 21. Thus, our provision of study product to adults aged 21 and older is in line with current NYS law.",{"count":357,"type":22},60,[359],"EARLY_PHASE1","This clinical trial assesses differences in the delivery of THC to the bloodstream depending on whether nicotine vapes are used before or after THC. While there has been much recent publicity about vaping products and concern about their safety considering their increasing use for THC administration, the THC delivery profile associated with THC liquid vaping products in human subjects is currently unknown. Importantly, how the delivery to the bloodstream of THC vaping liquids compare to delivery from smoked cannabis, which is the most used method of cannabis delivery, will serve as an important benchmark for evaluating the delivery and effects of THC vaping products, and their relative safety.",[362],"Cannabis Dependence",{"date":286,"type":33},{"date":35,"type":22},{"date":366,"type":22},"2028-03-01",{"name":39,"class":40},{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":23,"phases":377,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":381,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":41},"100540914","medsupport-intervention-to-identify-and-address-barriers-to-pediatric-medication-adherence-100540914","NCT06323044","MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence","MedSupport: A Novel Multilevel Intervention to Identify and Address Barriers to Pediatric Medication Adherence","Inclusion Criteria:\n\n* Parent of a child diagnosed with acute lymphoblastic leukemia (ALL)\n* Child patient age 365 days to \\\u003C 19 years at time of study entry.\n* Parent's child patient's therapy must include 6-mercaptopurine (6-MP) administered orally or by nasogastric (NG) tube.\n* Verbal fluency in English, or Spanish\n* Parent has a smartphone or computer access with an Internet connection.\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure.\n\nExclusion Criteria:\n\n* Parent is unwilling or unable to follow protocol requirements.",{"count":376,"type":22},150,[25],"This clinical trial identifies and addresses barriers to pediatric medication adherence among families of children with acute lymphoblastic leukemia. Pediatric nonadherence (noncompliance) to medication is a significant public health problem, and rigorous research repeatedly documents that nonadherence increases risk for hospitalization, healthcare cost, disease progression, and death. Pediatric acute lymphoblastic leukemia (ALL) patients who miss 5% of 6-mercaptopurine (6-MP) doses within the 2-year 6-MP regimen have a 2.7-fold risk of cancer that comes back after a period of improvement (relapse). To address these families' needs, researchers have developed MedSupport, a theory-based multilevel intervention with targets at the organizational, healthcare team, and caregiver levels that is designed to address root barriers to medication adherence. This study is being done to better understand families' experiences giving their child oral chemotherapy at home and to help families cope with the day-to-day challenges of giving their child medication.",[380],"Acute Lymphoblastic Leukemia",{"date":286,"type":33},{"date":383,"type":33},"2025-02-11",{"date":385,"type":22},"2029-03-31",{"name":39,"class":40},{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":17,"sex":18,"minAge":219,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":23,"phases":395,"briefSummary":396,"conditions":397,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":398,"startDateStruct":399,"completionDateStruct":400,"leadSponsor":402,"locationsCount":4},"100520335","phase-1-pkpd-of-vaping-thc-containing-liquids-vs-smoked-cannabis-100520335","NCT06055231","PK\u002FPD of Vaping THC-containing Liquids vs. Smoked Cannabis","A Randomized Within-Subject Cross-Over Study to Compare Short-Term PK\u002FPD Effects of Vaping THC-containing Liquids vs. Smoked Cannabis","Inclusion Criteria:\n\n* Age \\>= 21 years of age\n* Report concurrent use of commercial (medical or recreational) smoked cannabis and THC vaping cartridges for at least 3 months prior to enrollment\n* Report smoking cannabis and THC- vaping liquid use at the potency level of the study product at least weekly (4x\u002Fmonth)\n* Report of not currently trying to become pregnant (females). Women of childbearing potential must be willing to provide a urine sample and test negative prior to receiving any study-related products\u002Fprocedures\n* Willing to complete a THC saliva test to check for recent use (NarcoCheck Ref#:NCE-STHC-1) and semi -quantitative urinary tetrahydrocannabinol-carboxylic acid (THCA) rapid test (NarcoCheck® THC PreDosage) during baseline testing, prior to receiving any study-related products\n* Participant must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* • Illegal or non-prescription drug use within the past 90 days. As detected by NacroCheck® Évolutive® (detection in human urine of the 12 most currently abused drugs) at the first session and prior to receiving any study product\n\n  * Report 2 or more drinking occasions\u002Fweek with 4 or more drinks\u002Foccasion\n  * Report of daily nicotine use\n  * Current or prior diagnosis of any psychotic disorders\n  * Current or prior diagnosis of chronic heart conditions\n  * Current or prior diagnosis of any respiratory condition\n  * Pregnant or currently trying to become pregnant (females)\n  * Detection level 4-5 (\\>300 ng\u002FmL) from a semi-quantitative urinary THCA rapid test (NarcoCheck® THC PreDosage)\n  * Unwilling or unable to follow protocol requirements\n  * Any condition which in the Investigator's opinion deems the participant an unsuitable candidate for participation",{"count":242,"type":22},[72],"We will conduct a randomized, within-subjects clinical study to compare short-term pharmacokinetic (PK) and pharmacodynamic (PD) effects of Δ9-tetrahydrocannabinol (THC) vaping liquids vs. smoked cannabis containing 6 equivalent standard THC units (5 mg THC=1 Standard THC Unit (STU)) in healthy community members who are current users of both products. While smoking cannabis remains the most common mode of THC use among adults and youth, alternative modes of delivery, such as Electronic Vaping Products (EVPs), are becoming increasingly popular for the delivery of cannabinoids. Declining cannabis risk perceptions, increasing normalization of cannabis, greater legal access and availability to cannabis, ease of administration, and ability to conceal vaped THC use have likely contributed to increasing prevalence of use throughout the population across all age groups. Comparing vaping THC containing liquids with smoking cannabis can serve as an important benchmark for evaluating the delivery and effects of THC vaping products and, their relative safety",[246],{"date":286,"type":33},{"date":35,"type":22},{"date":401,"type":22},"2027-09-15",{"name":39,"class":40},{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":410,"targetDuration":4,"studyType":23,"phases":412,"briefSummary":413,"conditions":414,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":4},"100650307","mind-body-interventions-for-the-improvement-of-quality-of-life-stress-and-sleep-quality-among-survivors-of-breast-prostate-endometrial-or-colorectal-cancer-100650307","NCT07745023","Mind-Body Interventions for the Improvement of Quality of Life, Stress, and Sleep Quality Among Survivors of Breast, Prostate, Endometrial, or Colorectal Cancer","Influence of Mind-Body Interventions on Cancer-Related Symptom Management in Survivors","Inclusion Criteria:\n\n* Received a diagnosis of invasive, non-metastatic breast, colorectal, endometrial, or prostate cancer within the past 12 months\n* Have completed active anti-cancer therapy (hormonal, bisphosphonate, or androgen therapy is allowed)\n* Able to safely participate in light-weight physical activity (e.g. gentle yoga)\n\nExclusion Criteria:\n\n* Individuals with skeletal instabilities, cardio-pulmonary comorbidities, or other conditions that may preclude safe participation in light physical activity\n* Pregnant or nursing female participants\n* Unwilling or unable to follow protocol requirements\n\n  * Any condition that, in the Investigator's opinion, deems the participant an unsuitable candidate\n  * Unable to complete survey questionnaires in English",{"count":411,"type":22},30,[25],"This clinical trial studies how well mind-body interventions work in improving quality of life (QOL), stress, and sleep quality among survivors of breast, prostate, endometrial, or colorectal cancer. For many cancer survivors, the experience of cancer extends well beyond the completion of therapy. Common long-term effects include fatigue, cognitive impairment, anxiety, depression, sleep disturbance, and diminished physical function, all of which contribute to reduced QOL and overall health. Yoga, a mind-body intervention, utilizes breathwork, meditation, and gentle movement to help reduce activity in the body's nervous system. Breathwork and meditation have been shown to improve heart rate variability (a measure of the body's ability to adapt to stress). Movement-based practices may offer added benefit by supporting coordination and physical resiliency, aspects that are often reduced after cancer treatment and can lead to decreased QOL. This trial may help researchers determine whether a mind-body intervention that includes breathwork and meditation, as well as an intervention that includes breathwork and meditation plus gentle movement can work to improve QOL, stress, and sleep quality among survivors of breast, prostate, endometrial, or colorectal cancer.",[415,81],"Breast Cancer Stage I","2026-08-03",{"date":418,"type":33},"2026-08-04",{"date":420,"type":22},"2026-09-30",{"date":422,"type":22},"2029-02-02",{"name":39,"class":40},{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":23,"phases":431,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":439,"leadSponsor":441,"locationsCount":41},"100645055","phase-1-phase-i-trial-of-pacritinib-in-combination-with-venetoclax-and-azacitidine-for-the-treatment-of-accelerated-and-blast-phase-myeloproliferative-neoplasms-100645055","NCT07679334","Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2\n* Subjects must have accelerated phase MPN as defined by 10-19% blasts or blast phase MPN (AML) as defined by ≥ 20% blasts in the blood or bone marrow by manual aspirate differential, immunohistochemistry staining, or flow cytometry, with a documented prior diagnosis of essential thrombocythemia (ET), polycythemia vera (PV), or primary myelofibrosis (PMF), The absence of a spleen, lack of splenomegaly, or history of splenic irradiation is not exclusionary.\n* Subjects with blast phase MPN must be newly diagnosed\u002Funtreated (no prior blast reduction therapy for blast phase disease except for hydroxyurea and\u002For a JAK inhibitor; treatment of a prior accelerated phase is allowed). Prior treatment with a hypomethylating agent (with or without a JAK inhibitor) is allowed for accelerated phase MPN. Prior treatment with any JAK inhibitor (including pacritinib) is allowed for any phase of disease (chronic, accelerated, or blast); however, must not have discontinued pacritinib due to toxicity. If a participant previously required dose reduction during pacritinib therapy and tolerated it well, then may enroll into a cohort utilizing that dose level or lower.\n* WBC \\\u003C 25 x 109\u002FL prior to treatment initiation- subjects with WBC ≥ 25 x 109\u002FL may still be eligible after receiving cytoreduction measures such as hydroxyurea and\u002For leukapheresis if WBC becomes \\\u003C 25 x 109\u002FL prior to treatment initiation. Cytoreduction with hydroxyurea and\u002For leukapheresis is allowed prior to treatment. Hydroxyurea must be discontinued ≥ 12 hours prior to treatment initiation.\n* Demonstrate adequate organ function as defined below. All screening labs to be obtained within 28 days prior to registration:\n* Total bilirubin: ≤ 1.5 x upper limit of normal (ULN) unless considered to be due to Gilbert's Syndrome, hemolysis, or leukemic organ involvement. Total bilirubin WBC \\\u003C 25 x 109\u002FL prior to treatment initiation- subjects with WBC ≥ 25 x 109\u002FL may still be eligible after receiving cytoreduction measures such as hydroxyurea and\u002For leukapheresis if WBC becomes \\\u003C 25 x 109\u002FL prior to treatment initiation. Cytoreduction with hydroxyurea and\u002For leukapheresis is allowed prior to treatment. Hydroxyurea must be discontinued ≥ 12 hours prior to treatment initiation.\n* Demonstrate adequate organ function as defined below. All screening labs to be obtained within 28 days prior to registration:\n* Total bilirubin: ≤ 1.5 x upper limit of normal (ULN) unless considered to be due to Gilbert's Syndrome, hemolysis, or leukemic organ involvement. Total bilirubin must be \\\u003C 3 x upper limit normal in subjects with Gilbert's Syndrome, hemolysis, or leukemic organ involvement.\n* Aspartate aminotransferase (AST): ≤ 3 x ULN (≤ 5 x ULN if considered to be due to myelofibrosis or leukemic organ involvement).\n* Alanine aminotransferase (ALT): ≤ 3 x ULN (≤ 5 x ULN if considered to be due to myelofibrosis or leukemic organ involvement).\n* Creatinine clearance: ≥ 30 mL\u002Fmin by Cockcroft-gault formula or measured by 24-hour urine collection.\n* Participants of child-bearing potential must agree to use highly effective contraceptive methods prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n\nExclusion Criteria:\n\n* Diagnosis of de novo AML, acute promyelocytic leukemia, or accelerated or blast phase MPN without a documented prior diagnosis of ET, PV, or PMF.\n* Known CNS leukemia involvement. NOTE: Subjects with clinical suspicion or signs of neurologic deficit should undergo a screening lumbar puncture prior to enrollment to confirm lack of CNS leukemia.\n* Previous treatment with BCL-2\u002FBCL-X inhibitors (including venetoclax and navitoclax).\n* Prior allogeneic stem cell transplantation for blast phase disease. Prior allogeneic stem cell transplantation for chronic and accelerated phase MPN is allowed. Subjects must not have received transplant within 60 days. Cannot be receiving immunosuppression therapy, with the exception of prednisone ≤10mg\u002Fd (or equivalent), for the treatment or prophylaxis of GVHD. If the subject has been on immunosuppressant treatment or prophylaxis for GVHD, the treatment must have been discontinued at least 14 days prior to study treatment and there must be no evidence of Grade ≥ 2 GVHD.\n* Treatment with moderate or strong CYP3A4 inhibitors or strong CYP3A4 inducers within five half-lives or 14 days, whichever is shorter, prior to the initiation of study treatment.\n\nTreatment with chemotherapy, wide-field radiation, or biologic therapy, with the exception of hydroxyurea as above, and all trans-retinoic acid given initially for presumed APML, within 14 days of study entry. Prior JAK inhibitor (other than pacritinib) must be held for five half-lives prior to study entry. Administration of steroids to prevent withdrawal symptoms is allowed.\n\n* Treatment with investigational drug within five half-lives or 14 days, whichever is shorter, prior to study entry.\n* Baseline prolonged QTc of \\> 480 msec. QTc measured by Fridericia's formula (QTc=QT\u002F\\[RR1\u002F3\\]) based on the mean of triplicate reads. Repeat EKGs after correction of electrolytes or discontinuation of QT prolonging medications are allowed to meet entry criteria.\n* Grade ≥2 bleeding event within the previous 3 months. Treatment with anticoagulation or antiplatelet agents (except for aspirin at dosages ≤100 mg per day or prophylactic doses of enoxaparin or heparin) within five half-lives or 7 days, whichever is shorter.\n* Any GI or metabolic condition that could interfere with absorption of oral medication.\n* Known severe (Child-Turcotte-Pugh class C) hepatic cirrhosis. Testing not required.\n* Pre-existing uncontrolled pathology such as heart failure (congestive\u002Fischemic, NYHA classes III and IV), clinically significant abnormalities on a 12-lead electrocardiogram, significant pulmonary disease, severe\u002Funstable arrhythmias\u002Fangina pectoris\u002Fhypertension, acute or chronic pancreatitis, etc. Acute myocardial infarction or stroke within 6 months of study entry.\n* Known active HIV, Hepatitis B, or Hepatitis C infection; testing not required.\n* Active uncontrolled or severe systemic infection. Enrollment is possible after control of infection, at discretion of the treating physician.\n* History of another active malignancy in the previous 2 years, with the exception of:\n\nadequately treated in situ carcinoma of the cervix, breast, prostate; basal cell carcinoma pf the skin or localized squamous cell carcinoma of the skin.\n\n* Pregnant or nursing female participants",{"count":96,"type":22},[72],"This phase I trial studies the side effects and best dose of pacritinib when given together with venetoclax and azacitidine in treating patients with accelerated and blast phase myeloproliferative neoplasms (MPN-AP\u002FBP). Pacritinib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving pacritinib together with venetoclax and azacitidine may be safe, tolerable, and\u002For effective in treating patients with MPN-AP\u002FBP",[434],"Myeloproliferative Neoplasm","2026-07-30",{"date":437,"type":33},"2026-07-31",{"date":104,"type":22},{"date":440,"type":22},"2029-09-01",{"name":39,"class":40},{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":17,"sex":18,"minAge":219,"maxAge":336,"enrollmentInfo":449,"targetDuration":4,"studyType":23,"phases":450,"briefSummary":451,"conditions":452,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":41},"100591213","electrotherapy-stimulation-together-with-life-coaching-for-the-support-of-burnout-symptoms-in-healthcare-workers-100591213","NCT06977503","Electrotherapy Stimulation Together With Life Coaching for the Support of Burnout Symptoms in Healthcare Workers","A Pilot Study Using a Cranial Electrotherapy Stimulation (CES) Device in Conjunction With Life Coaching to Alleviate Burnout Symptoms in HealthCare Workers (HCWs)","Inclusion Criteria:\n\n* Age 21 ≤ and ≤ 75 years old\n* Patient-facing healthcare workers (e.g., medical doctor, advanced practice provider, nurse)\n* Experiencing symptoms of burnout, as defined by a score of 1, 2, or 3 on question #2 of the Mini-Z II Survey\n* Working on the Buffalo-Niagara Medical Campus (e.g. Roswell Park, Oishei Children's Hospital, Buffalo General, etc.)\n* Ability to attend three (3) in-person appointments, one (1) hour in duration, at Roswell Park at week 1, week 6 and week 12 corresponding to the initial, midpoint, and final assessments\n* Ability to use the CES daily for an hour each day\n\n  * Although the device is water-resistant, participants must agree to not use the device in the bath or shower\n* Ability to read and write in English\n* Participant has access to a computer with internet access and an email address\n\n  * Ability to attend three (3) virtual 60-minute group life coaching sessions, via Zoom\n  * Ability to complete three (3) 10-15-minute pre-recorded video assignments, which will be distributed via email (each assignment will be due by the end of the week that they are distributed)\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Subjects who self-report as pregnant or nursing. Pregnancy be verified with a urine test for all persons of childbearing potential with a uterus\n* Subjects with a self-reported history of the following: Meniere's disease, history of vertigo or prone to dizziness, seizure disorder, pacemaker \u002F implantable cardioverter-defibrillator (automatic implantable cardioverter defibrillator \\[AICD\\]), cochlear implant, or any implanted electrical devices that cannot be shut off\n* Inability to tolerate the required minimum stimulation amplitude (200 uA) during the initial device training at the baseline visit.\n* Any self-reported medical or psychiatric condition which in the PI or study physician's opinion deems the participant an unsuitable candidate to participate in this trial.\n* Unwilling or unable to follow protocol requirements",{"count":242,"type":22},[25],"This clinical trial evaluates the effect of life coaching together with Cranial Electrotherapy Stimulation (CES) as an intervention to decrease self-reported symptoms of burnout, moral distress, resilience, and employee retention in oncology healthcare workers. Burnout and moral distress are occupational hazards for oncology healthcare workers. Emotional exhaustion, depersonalization, and lack of personal accomplishment at work are symptoms of burnout. Moral distress may be defined as knowing the right thing to do but being unable to do so based upon internal or external constraints. The device is attached to the earlobes that uses cranial electrotherapy stimulation (CES) at a microcurrent to alleviate symptoms of anxiety, insomnia, pain, and possibly depression. Life coaching is partnering with clients in a thought-provoking and creative process that inspires them to maximize their personal and professional potential and can increase resiliency skills such as boundary setting and prioritizing, increases in self-compassion and self-care, and potentially indirectly positively impact patient care. Undergoing the use of CES via the CES device, coupled with life coaching, may help alleviate burnout symptoms and moral distress in oncology healthcare workers.",[453],"Psychiatric Disorder","2026-07-28",{"date":456,"type":33},"2026-07-29",{"date":458,"type":33},"2026-02-04",{"date":460,"type":22},"2027-10-04",{"name":39,"class":40},{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":23,"phases":470,"briefSummary":471,"conditions":472,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":475,"leadSponsor":477,"locationsCount":41},"100559525","community-based-exercise-and-nutrition-training-and-education-program-for-cancer-survivors-100559525","NCT06565260","Community-Based Exercise and Nutrition Training and Education Program for Cancer Survivors","Feasibility of a Community-Based Cancer Survivor Exercise and Nutrition Education Program: Effects on Self-Efficacy, Quality of Life and Functional Performance","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Have had a previous cancer diagnosis and completed all therapy OR are a caregiver for a patient who has had a previous cancer diagnosis.\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related interventions.\n\nExclusion Criteria:\n\n* Have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia including atrial fibrillation (AFIB), multiple myeloma, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Have orthopedic or neuromuscular disorders or arthritis that preclude participation in exercise.\n* Are pregnant or nursing.\n* History of a stem cell transplant.\n* Currently on steroids.\n* Unwilling or unable to follow protocol requirements.\n* Any condition which in the investigator's opinion deems the participant an unsuitable candidate to participate in the study.",{"count":376,"type":22},[25],"This clinical trial evaluates whether a supervised community-based exercise and nutrition program is usable and effective for improving cancer survivors' confidence for maintaining their physical activity and nutrition. Cancer survivors often experience problems with the musculoskeletal system (bones, joints, muscles, connective tissue), the cardiopulmonary system (heart, blood vessels and lungs) and the metabolic system (how the body's cells change food into energy) following treatment. There is substantial evidence that physical activity, diet, and weight management can improve quality of life (emotional and physical well-being) and physical fitness. Information gathered from this study may help researchers determine whether participating in a community-based exercise\u002Fnutrition training and education program may improve levels of fitness, cardiovascular health, and quality of life for cancer survivors.",[341,342],{"date":456,"type":33},{"date":104,"type":22},{"date":476,"type":22},"2029-08-30",{"name":39,"class":40},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":17,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":23,"phases":486,"briefSummary":487,"conditions":488,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":41},"100531981","community-based-physical-activity-intervention-for-underserved-cancer-survivors-100531981","NCT06206863","Community-Based Physical Activity Intervention for Underserved Cancer Survivors","Community-Based Physical Activity Across the Cancer Continuum","Inclusion Criteria:\n\n* Have had a previous cancer diagnosis OR are a caregiver for a patient who has had a previous cancer diagnosis\n* Not in active treatment for cancer\n* Over 18 years of age\n\nExclusion Criteria:\n\n* Have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, atrial fibrillation (AFIB), multiple myeloma, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Have orthopedic or neuromuscular disorders or arthritis that preclude participation in exercise\n* Are pregnant or nursing - self reported by participant\n* Are unwilling or unable to follow protocol requirements\n* Have any condition which in the investigator's opinion deems the subject an unsuitable candidate to participate in this study",{"count":21,"type":22},[25],"This clinical trial evaluates a community-based physical activity program for underserved cancer survivors. Cancer and its treatment significantly influence physical, psychosocial, and cognitive functioning. Historically, community sites (local and national) have not been staffed to offer support services such as physical, and occupational therapies (everyday life activities to promote health and well-being) or nutrition counselling, and do not offer a whole-person model of care. In this study, researchers have partnered with the YMCA to provide tailored home-based exercise programs for underserved cancer patients and survivors. Accessing exercise professionals may allow patients to prevent acute problems from becoming chronic, long-lasting physically weak impairments that directly influence patients' quality of life.",[54,342],"2026-07-27",{"date":456,"type":33},{"date":492,"type":33},"2024-08-20",{"date":494,"type":22},"2027-12-30",{"name":39,"class":40},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":503,"targetDuration":4,"studyType":243,"phases":4,"briefSummary":505,"conditions":506,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":328},"100540736","ai-derived-biomarker-to-select-neoadjuvant-treatment-for-borderline-resectable-pancreatic-ductal-adenocarcinoma-100540736","NCT06320717","AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma","A Retrospective\u002FProspective Study of an Artificial Intelligence Derived Histological Biomarker to Select Neoadjuvant Treatment for Patients With Borderline Resectable or Resectable Pancreatic Ductal Adenocarcinoma","Inclusion Criteria:\n\n* Have histologically or cytologically confirmed PDAC that is borderline resectable (BR) (Cohort A) OR have histologically or cytologically confirmed PDAC that is resectable (Cohort B) using the National Comprehensive Cancer Network criteria \\[35\\].\n* Availability of archival tumor tissue (diagnostic for PDAC) required\n* Have a documented ECOG Performance Status of ≤ 1\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form (ICF) prior to receiving any study related procedure.\n\nExclusion Criteria:\n\n* Has received prior systemic treatment (standard of care or experimental) for PDAC\n* Participant has a concurrent malignancy requiring active treatment during the study.",{"count":504,"type":22},100,"To collect samples and information from patients who will be undergoing standard of care neoadjuvant treatment with either FOLFIRINOX or Gemcitabine + Nab-paclitaxel.\n\nThe information collected will be used to determine if there are any \"biomarkers\" in your blood or tumor tissue that, when compared to your response to the neoadjuvant treatment, could be used to choose the best treatment option for future patients with similar biomarkers.",[507],"Pancreatic Ductal Adenocarcinoma","2026-07-22",{"date":510,"type":33},"2026-07-23",{"date":512,"type":33},"2024-01-02",{"date":514,"type":22},"2026-12-02",{"name":39,"class":40},{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":523,"targetDuration":4,"studyType":23,"phases":524,"briefSummary":525,"conditions":526,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":532,"completionDateStruct":533,"leadSponsor":534,"locationsCount":41},"100648275","phase-2-hotspot-stereotactic-ablative-radiotherapy-versus-traditional-stereotactic-ablative-radiotherapy-for-the-treatment-of-early-stage-non-small-cell-lung-cancer-100648275","NCT07718672","Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer","(PRESTO) A Randomized Phase II Trial Evaluating Hotspots in Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2\n* Diagnosed with T1-3N0 biopsy-proven NSCLC of the lung. Multiple primary lung tumors are allowed; however, each lesion requires histologic confirmation\n* Metachronous lung tumors as defined as a new lung lesion in the setting of a historically treated lung cancer are allowed under certain conditions. The previous lung cancer must have been treated greater than 6 months prior to protocol therapy and this cancer must be considered controlled\n* Eligible for SABR\n* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Patients with a history of a prior lung cancer will be excluded only if the previous treatment is within 6 months of the protocol therapy\n* Mixed small cell and non-small cell lung cancer\n* History of allogeneic organ transplantation\n* History of primary immunodeficiency\n* Patients must not have undergone prior radiation to overlapping regions of the chest that, in the opinion of the treatment physician, will interfere with protocol treatment\n* Active autoimmune disease that has required systemic treatment in the last 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed\n* Known EGFR or ALK mutation\n* Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD\n* Pregnant or nursing female participant\n* Unwilling or unable to follow protocol requirements",{"count":21,"type":22},[73],"This clinical trial compares stereotactic ablative radiotherapy (SBRT) with hot spots to standard of care SBRT for the treatment of patients with early-stage non-small cell lung cancer. SBRT with hot spots intentionally makes sure the tumor gets a higher radiation dose during treatment. This potentially may result in better control of the tumor, but also more side effects. SBRT with or without hot spots may be more effective in treating patients with early-stage non-small cell lung cancer, compared to standard of care SBRT.",[527,528,529],"Early Stage Lung Non-Small Cell Carcinoma","Stage I Lung Cancer AJCC v8","Stage II Lung Cancer AJCC v8","2026-07-17",{"date":508,"type":33},{"date":104,"type":22},{"date":440,"type":22},{"name":39,"class":40},""]